Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Chemical Science|February 3, 2025
Potential theranostics of breast cancer with copper-64/67 sarcophagine-trastuzumabStacey E Rudd, Jessica Van Zuylekom, Carleen Cullinane, et al.
Methods in Molecular Biology (Clifton, N.J.)|June 24, 2023
On Target: An Intrapulmonary Transplantation Method for Modelling Lung Tumor Development in its Native MicroenvironmentJackson A McDonald, Leanne Scott, Jessica Van Zuylekom, et al.
Theranostics|September 29, 2023
A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177Lutetium-DOTA-octreotate radionuclide therapyKelly Waldeck, Jessica Van Zuylekom, Carleen Cullinane, et al.
RSC Advances|January 9, 2026
Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical settingMarwa N Rahimi, Jo-Anne Pinson, Joseph Hilton-Proctor, et al.
RSC Advances|February 16, 2026
Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical settingMarwa N Rahimi, Jo-Anne Pinson, Joseph Hilton-Proctor, et al.
Theranostics|March 20, 2024
Precision peptide theranostics: developing N- to C-terminus optimized theranostics targeting cholecystokinin-2 receptorMarwa N Rahimi, Alicia Corlett, Jessica Van Zuylekom, et al.
Dalton Transactions (Cambridge, England : 2003)|May 13, 2025
A gallium fluoride-18 complex containing a pentadentate macrocyclic ligand with a dimethylaminostilbene functional group designed for diagnostic imaging of Alzheimer's diseaseHuiJing Koay, Mohammad B Haskali, Jessica Van Zuylekom, et al.
Journal of Medicinal Chemistry|July 26, 2023
Development of Highly Potent Clinical Candidates for Theranostic Applications against Cholecystokinin-2 Receptor Positive CancersAlicia Corlett, Jo-Anne Pinson, Marwa N Rahimi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2020
Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor ModelCarleen Cullinane, Charmaine M Jeffery, Peter D Roselt, et al.
Journal of Medicinal Chemistry|April 7, 2021
A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive CancerAlicia Corlett, Marc-Antoine Sani, Jessica Van Zuylekom, et al.
Pageof 2